Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EndoTAG-1 + paclitaxel + gemcitabine
- Development stage
- Unknown
- Lead developer
- SynCore Biotechnology
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
A combination regimen consisting of **EndoTAG-1**, **paclitaxel**, and **gemcitabine** investigated primarily for advanced or metastatic cancers such as pancreatic cancer. **EndoTAG-1** is a cationic liposomal formulation of paclitaxel designed for targeted delivery to tumor vasculature. **Paclitaxel** is a microtubule-stabilizing agent that disrupts cell division, while **gemcitabine** is a nucleoside analog that inhibits DNA synthesis. The combination leverages different antineoplastic mechanisms: targeted delivery to tumor vessels with EndoTAG-1, cell cycle arrest with paclitaxel, and inhibition of DNA replication with gemcitabine. The regimen has been evaluated in clinical trials, mainly for pancreatic cancer, with evidence of improved efficacy compared to gemcitabine alone.
- Brand names
- Abraxane
- Other names
- nab-paclitaxelalbumin-bound paclitaxelpaclitaxelgemcitabine
02
Targets
TUBB (Tubulin (alpha and beta subunits))DCK (Deoxycytidine kinase)DNA
Beyond the preview
Go deeper on EndoTAG-1 + paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EndoTAG-1 + paclitaxel + gemcitabine.